trending Market Intelligence /marketintelligence/en/news-insights/trending/eyqygt_uxAP4S1AUV7EcpQ2 content esgSubNav
In This List

Alpine Immune seeks to raise $25M in private placement to fund drug programs

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Podcast

Street Talk | Episode 98: Regulatory scrutiny having cooling effect on community bank M&A

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022


Alpine Immune seeks to raise $25M in private placement to fund drug programs

Alpine Immune Sciences Inc. is selling its units in a private placement to raise about $25.3 million in gross proceeds to fund its drug programs.

The biotechnology company will issue units representing about 4.7 million common shares and warrants to buy about 1.8 million shares. Each unit is priced at $5.37 apiece and consists of 1 share plus a warrant to buy 0.39 share.

Each warrant can be exercised to buy 1 common share at $12.74 apiece.

The placement, expected to close Jan. 18, was led by private equity firm Decheng Capital LLC, with existing investors OrbiMed Advisors LLC, Frazier Management LLC, Alpine BioVentures GP LLC and BVF Partners LP, also participating.

Seattle-based Alpine, which is focused on developing immune therapeutics, intends to appoint Min Cui, founder and managing director of Decheng Capital, to its board after the completion of the transaction.

Alpine intends to use the net proceeds from the placement to fund the development of ALPN-101 for treating autoimmune and inflammatory diseases and ALPN-202 to treat cancer.

Piper Jaffray & Co. acted as sole placement agent for the transaction.